Purpose To assess impact of eslicarbazepine acetate (ESL) on patient-rated quality of life (QOL) and clinician-rated global improvement in patients included in the EPOS (Eslicarbazepine acetate in Partial-Onset Seizures) study.
Method EPOS was an open-label, prospective study which included adults with uncontrolled partial-onset seizures receiving antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy. QOL was assessed (at baseline and after 3 and 6 months) using the QOL in Epilepsy Inventory-10 (QOLIE-10). Global improvement was assessed (after 3 and 6 months) using the Clinical Global Impression-Global Improvement scale (CGI-GI).
Results Overall, 219 patients were included in the study (mean age 45.9 years; 57.5% male). Complete QOLIE-10 data were available for 109 patients. Mean QOLIE-10 score decreased from 2.9 (n=128) at baseline to 2.4 (−14.6%; n=114) after 3 months and 2.1 (−20.8%; n=109) after 6 months. The majority of patients were ‘much improved’ or ‘very much improved’ on the CGI-GI after 3 months (‘much improved’, 49.8%; ‘very much improved’, 14.9%; n=211) and 6 months (‘much improved’, 41.7%; ‘very much improved’, 33.9%'; n=192).
Conclusion In this real-world study, ESL as add-on to antiepileptic monotherapy provided beneficial effects on patient-rated QOL and clinician-rated global improvement.
Supported by Eisai.